论文部分内容阅读
目的观察吸入布地奈德混悬液治疗小儿支原体肺炎的临床疗效。方法选择2008年5月至2009年10月住院的确诊为MPCAP的患儿128例,用颗粒凝集法检测血清IgM抗体(MP.IgM)阳性和(或)PCR检测出肺炎支原体DNA为诊断肺炎支原体感染依据;随机分为治疗组64例和对照组64例,治疗组在常规治疗的基础上给予布地奈德混悬液雾化吸人,2次/d,疗程5～7d。对照组给予常规治疗,观察雾化吸入对缓解患儿的症状体征的疗效。结果①治疗组总有效率为95.3%,对照组的总有效率84.4%,两组总有效率比较差异有统计学意义(r=5.3,P<0.05);②不良反应:治疗组患儿未见不良反应。结论配合吸入布地奈德混悬液治疗小儿支原体肺炎,可显著缓解患儿的咳嗽喘息等症状及体征,具有良好的安全性,依从性好,值得在儿科临床中应用。
Objective To observe the clinical efficacy of inhaled budesonide suspension in treating children with mycoplasma pneumonia. Methods One hundred and eighty-eight children diagnosed as MPCAP from May 2008 to October 2009 were enrolled in this study. Mycoplasma pneumoniae (Mycoplasma pneumoniae) was detected by positive and / or negative serum IgM antibody (MP.IgM) Infection was divided into 64 cases in the treatment group and 64 cases in the control group. The treatment group was given inhalation of budesonide suspension on the basis of routine treatment twice a day for 5-7 days. The control group was given conventional treatment to observe the effect of atomized inhalation on relieving the symptoms and signs of children. Results ① The total effective rate was 95.3% in the treatment group and 84.4% in the control group. The total effective rate in the two groups was significantly different (r = 5.3, P <0.05). ② Adverse reactions: See adverse reactions. Conclusion Combined inhalation of budesonide suspension in the treatment of children with mycoplasma pneumonia can significantly relieve cough and wheezing in children with other symptoms and signs, with good safety, good compliance, it is worth in pediatric clinical application.